Bristol Myers Squibb Company $BMY Shares Sold by Cullen Capital Management LLC

Cullen Capital Management LLC reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 12.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,176,726 shares of the biopharmaceutical company’s stock after selling 164,121 shares during the period. Cullen Capital Management LLC’s holdings in Bristol Myers Squibb were worth $63,473,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $1,947,272,000. Bank of New York Mellon Corp lifted its holdings in shares of Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after acquiring an additional 7,837,485 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. Man Group plc lifted its holdings in shares of Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after acquiring an additional 5,503,391 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in shares of Bristol Myers Squibb by 530.6% during the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after acquiring an additional 4,588,601 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Bristol Myers Squibb Trading Up 0.3%

NYSE BMY opened at $57.05 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company’s 50 day moving average price is $57.73 and its 200 day moving average price is $56.87. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The firm has a market capitalization of $116.49 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the firm posted $1.80 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BMY. Piper Sandler reiterated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Cantor Fitzgerald increased their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective on the stock. Barclays began coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. Finally, HSBC increased their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.